[go: up one dir, main page]

WO2008125366A3 - Nouveaux traitements de maladies - Google Patents

Nouveaux traitements de maladies Download PDF

Info

Publication number
WO2008125366A3
WO2008125366A3 PCT/EP2008/004992 EP2008004992W WO2008125366A3 WO 2008125366 A3 WO2008125366 A3 WO 2008125366A3 EP 2008004992 W EP2008004992 W EP 2008004992W WO 2008125366 A3 WO2008125366 A3 WO 2008125366A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
substance
ebv
cidal
involve
Prior art date
Application number
PCT/EP2008/004992
Other languages
English (en)
Other versions
WO2008125366A2 (fr
Inventor
Francesca Aloisi
Barbara Serafini
Original Assignee
Ist Superiore Sanita
Francesca Aloisi
Barbara Serafini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Superiore Sanita, Francesca Aloisi, Barbara Serafini filed Critical Ist Superiore Sanita
Publication of WO2008125366A2 publication Critical patent/WO2008125366A2/fr
Publication of WO2008125366A3 publication Critical patent/WO2008125366A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Une infection aberrante de cellules B par le virus Epstein-Barr (EBV) conduit à une maladie auto-immune, notamment la sclérose en plaques, la myasthénie grave et la thyroïdite d'Hashimoto. Cette maladie pouvant être traitée ou l'immunité contre cette maladie pouvant être acquise.
PCT/EP2008/004992 2007-04-13 2008-04-11 Nouveaux traitements de maladies WO2008125366A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0707208.5 2007-04-13
GBGB0707208.5A GB0707208D0 (en) 2007-04-13 2007-04-13 Novel disease treatments

Publications (2)

Publication Number Publication Date
WO2008125366A2 WO2008125366A2 (fr) 2008-10-23
WO2008125366A3 true WO2008125366A3 (fr) 2009-07-16

Family

ID=38116725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004992 WO2008125366A2 (fr) 2007-04-13 2008-04-11 Nouveaux traitements de maladies

Country Status (2)

Country Link
GB (1) GB0707208D0 (fr)
WO (1) WO2008125366A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390334C1 (ru) * 2008-12-17 2010-05-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ лечения рассеянного склероза
WO2013192100A1 (fr) * 2012-06-18 2013-12-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Procédés et compositions pour la détection du virus jc
US9617607B2 (en) * 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
WO2014110127A1 (fr) 2013-01-08 2014-07-17 Enzo Biochem, Inc. Diagnostic et traitement de maladies virales
ITRM20130206A1 (it) * 2013-04-05 2014-10-06 Univ Roma Varianti genotipiche del virus di epstein barr e loro usi come possibili predittori di rischio, biomarcatori e target terapeutici nella sclerosi multipla
US20230193398A1 (en) * 2020-04-22 2023-06-22 Nicca Chemical Co., Ltd. Nucleic acid detection method and oligonucleotide probe
WO2022146869A1 (fr) * 2020-12-29 2022-07-07 The Board Of Trustees Of The Leland Stanford Junior University Agents diagnostiques et thérapeutiques pour le virus epstein-barr (ebv) en sclérose en plaques (sep) et autres maladies auto-immunes
CN114990240B (zh) * 2022-06-01 2024-05-10 昆明理工大学 用于检测妇科疾病外源病原体的多重qPCR检测试剂

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
WO1989006968A1 (fr) * 1988-02-03 1989-08-10 Xoma Corporation Utilisation therapeutique d'immunotoxiques anti-cellules t contre des maladies autoimmunes
EP0501233A1 (fr) * 1991-02-26 1992-09-02 Bayer Corporation Hybridomes et anticorps monoclonaux inhibant la prolifération de cellules T stimulées par l'anti-CD3
WO1993004695A1 (fr) * 1991-08-28 1993-03-18 The Wistar Institute Therapie de la polyarthrite rhumatoide basee sur le recepteur de lymphocytes t
IL89953A (en) * 1989-02-03 1994-04-12 Xoma Corp Pharmaceutical composition comprising anti-t cell immunotoxin for use in treating autoimmune disease
WO1998030586A2 (fr) * 1997-01-13 1998-07-16 Oklahoma Medical Research Foundation Diagnostics et therapies du virus epstein-barr dans les affections auto-immunes
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
WO2000067796A1 (fr) * 1999-05-07 2000-11-16 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes b
WO2001037868A1 (fr) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Analyses et therapies utilisees dans le cas d'une infection virale latente
WO2001058481A2 (fr) * 2000-02-09 2001-08-16 Oklahoma Medical Research Foundation Diagnostics et therapie du virus d'epstein-barr dans des troubles auto-immuns
WO2002047720A2 (fr) * 2000-12-11 2002-06-20 Tufts University Traitement et prevention de l'infection par le virus epstein-barr (ebv) et des troubles qui lui sont associes
WO2003025541A2 (fr) * 2001-09-18 2003-03-27 Chiron Corporation Methodes de traitement de la sclerose en plaques
WO2003028753A1 (fr) * 2001-09-29 2003-04-10 Andreas Schwarting UTILISATION D'INTERFERON β POUR TRAITER LE LUPUS ERYTHEMATEUX SYSTEMIQUE (LES)
WO2003045978A2 (fr) * 2001-11-26 2003-06-05 Chiron Corporation Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques
US20030148963A1 (en) * 2000-05-31 2003-08-07 Andrej Tarkowski Use of etoposide
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
WO2004004798A2 (fr) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
WO2004032828A2 (fr) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Conjugues anticorps anti-cd20-medicament pour le traitement du cancer et des troubles immunitaires
US20040151694A1 (en) * 1994-04-12 2004-08-05 Staley Brod Method of treating auto-immune diseases using type one interferons
WO2005009466A1 (fr) * 2003-07-24 2005-02-03 Universita' Degli Studi Di Perugia Methodes et compositions pour augmenter l'efficacite d'anticorps therapeutiques au moyen de cellules nk alloreactives
WO2005117978A2 (fr) * 2004-06-04 2005-12-15 Genentech, Inc. Methode de traitement de la sclerose en plaques
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
WO2006076651A2 (fr) * 2005-01-13 2006-07-20 Genentech, Inc. Procede de traitement
US20060240008A1 (en) * 2003-04-09 2006-10-26 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
US20060257363A1 (en) * 2004-03-10 2006-11-16 Pepgen Corporation Treatment using an interferon
WO2007014238A2 (fr) * 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Utilisation de dose unique de molecules de liaison specifique au cd20

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
WO1989006968A1 (fr) * 1988-02-03 1989-08-10 Xoma Corporation Utilisation therapeutique d'immunotoxiques anti-cellules t contre des maladies autoimmunes
IL89953A (en) * 1989-02-03 1994-04-12 Xoma Corp Pharmaceutical composition comprising anti-t cell immunotoxin for use in treating autoimmune disease
EP0501233A1 (fr) * 1991-02-26 1992-09-02 Bayer Corporation Hybridomes et anticorps monoclonaux inhibant la prolifération de cellules T stimulées par l'anti-CD3
WO1993004695A1 (fr) * 1991-08-28 1993-03-18 The Wistar Institute Therapie de la polyarthrite rhumatoide basee sur le recepteur de lymphocytes t
US20040151694A1 (en) * 1994-04-12 2004-08-05 Staley Brod Method of treating auto-immune diseases using type one interferons
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
WO1998030586A2 (fr) * 1997-01-13 1998-07-16 Oklahoma Medical Research Foundation Diagnostics et therapies du virus epstein-barr dans les affections auto-immunes
WO2000067796A1 (fr) * 1999-05-07 2000-11-16 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes b
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
WO2001037868A1 (fr) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Analyses et therapies utilisees dans le cas d'une infection virale latente
WO2001058481A2 (fr) * 2000-02-09 2001-08-16 Oklahoma Medical Research Foundation Diagnostics et therapie du virus d'epstein-barr dans des troubles auto-immuns
US20030148963A1 (en) * 2000-05-31 2003-08-07 Andrej Tarkowski Use of etoposide
WO2002047720A2 (fr) * 2000-12-11 2002-06-20 Tufts University Traitement et prevention de l'infection par le virus epstein-barr (ebv) et des troubles qui lui sont associes
WO2003025541A2 (fr) * 2001-09-18 2003-03-27 Chiron Corporation Methodes de traitement de la sclerose en plaques
WO2003028753A1 (fr) * 2001-09-29 2003-04-10 Andreas Schwarting UTILISATION D'INTERFERON β POUR TRAITER LE LUPUS ERYTHEMATEUX SYSTEMIQUE (LES)
WO2003045978A2 (fr) * 2001-11-26 2003-06-05 Chiron Corporation Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
WO2004004798A2 (fr) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
WO2004032828A2 (fr) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Conjugues anticorps anti-cd20-medicament pour le traitement du cancer et des troubles immunitaires
US20060240008A1 (en) * 2003-04-09 2006-10-26 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
WO2005009466A1 (fr) * 2003-07-24 2005-02-03 Universita' Degli Studi Di Perugia Methodes et compositions pour augmenter l'efficacite d'anticorps therapeutiques au moyen de cellules nk alloreactives
US20060257363A1 (en) * 2004-03-10 2006-11-16 Pepgen Corporation Treatment using an interferon
WO2005117978A2 (fr) * 2004-06-04 2005-12-15 Genentech, Inc. Methode de traitement de la sclerose en plaques
WO2006076651A2 (fr) * 2005-01-13 2006-07-20 Genentech, Inc. Procede de traitement
WO2007014238A2 (fr) * 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Utilisation de dose unique de molecules de liaison specifique au cd20

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CROSS A H ET AL: "Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 180, no. 1-2, 1 November 2006 (2006-11-01), pages 63 - 70, XP025039481, ISSN: 0165-5728, [retrieved on 20061101] *
DATABASE WPI Week 199422, Derwent World Patents Index; AN 1994-178486, XP002524094 *
FRIEDMAN J E ET AL: "A randomized clinical trial of valacyclovir in multiple sclerosis.", MULTIPLE SCLEROSIS (HOUNDMILLS, BASINGSTOKE, ENGLAND) JUN 2005, vol. 11, no. 3, June 2005 (2005-06-01), pages 286 - 295, XP009105819, ISSN: 1352-4585 *
HAAHR SVEN ET AL: "Multiple sclerosis is linked to Epstein-Barr virus infection", REVIEWS IN MEDICAL VIROLOGY, vol. 16, no. 5, September 2006 (2006-09-01), pages 297 - 310, XP002524093, ISSN: 1052-9276 *
HARRISON ET AL: "ACYCLOVIR IN RHEUMATOID ARTHRITIS", JOURNAL OF RHEUMATOLOGY, TORONTO, CA, vol. 20, 1 January 1993 (1993-01-01), pages 761/762, XP000881431, ISSN: 0315-162X *
LYCKE J ET AL: "Acyclovir concentrations in serum and cerebrospinal fluid at steady state.", THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY DEC 1989, vol. 24, no. 6, December 1989 (1989-12-01), pages 947 - 954, XP009105821, ISSN: 0305-7453 *
LYCKE JAN ET AL: "Acyclovir treatment of relapsing-remitting multiple sclerosis: A randomized, placebo-controlled, double-blind study", JOURNAL OF NEUROLOGY, vol. 243, no. 3, 1996, pages 214 - 224, XP009105820, ISSN: 0340-5354 *
SIBILIA ET AL: "Treatment of systemic lupus erythematosus in 2006", JOINT BONE SPINE, ELSEVIER, PARIS, FR, vol. 73, no. 6, 19 December 2006 (2006-12-19), pages 591 - 598, XP005808730, ISSN: 1297-319X *

Also Published As

Publication number Publication date
WO2008125366A2 (fr) 2008-10-23
GB0707208D0 (en) 2007-05-23

Similar Documents

Publication Publication Date Title
WO2008125366A3 (fr) Nouveaux traitements de maladies
JP2022088411A5 (fr)
IL257037A (en) Benzodiazepine derivatives as rsv inhibitors
WO2004107956A3 (fr) Methodes et dispositifs de traitement de lesions cutanees
EP2853531A3 (fr) Composés antiviraux
EP1594512A4 (fr) Composes destines au traitement d'une infection virale
AU2003249977A1 (en) Imidazole compounds for the treatment of hepatitis c virus infections
IL176206A0 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
WO2008062446A3 (fr) Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments
WO2007027248A3 (fr) Analogues de nucleoside cyclique 3', 5' pour le traitement du virus de l'hepatite c (vhc)
WO2005014806A3 (fr) Sequences conservees du vhb et du vhc utiles pour le silençage genique
WO2009024834A8 (fr) Acides nucléiques impliques dans les infections virales
WO2011080593A3 (fr) Substances et procédés pour prévention et traitement d'infections virales
WO2010101649A3 (fr) Inhibition du récepteur sigma 1 en tant que nouvelle approche thérapeutique contre une infection par le virus de l'hépatite c
IL178094A (en) Enantiomers, their use in the treatment or prevention of viral diseases, allergic immune diseases, autoimmune diseases or graft rejection, and methods of preparation of these substances
WO2011044369A8 (fr) Filtre de perfusion sanguine d'immunoactivation pour le traitement de tumeurs malignes
Jeong et al. Acanthamoeba: keratopathogenicity of isolates from domestic tap water in Korea
WO2003053360A3 (fr) Traitement du virus d'epstein-barr, infection a l'herpesvirus lie au sarcome de kaposi et proliferation cellulaire anormale associee
TW200633718A (en) Treatment of hepatitis c in the asian population
WO2004066942A3 (fr) Purification et utilisations de cellules dendritiques et de monocytes
WO2002029074A3 (fr) Immunisation genetique contre le carcinome cervical
WO2010014248A3 (fr) Activité antivirale de la protéine scytovirine et procédés d'utilisation
WO2009025374A1 (fr) Procédé de culture de périoste humain
WO2007144569A3 (fr) Produit antiviral
WO2002008292A3 (fr) Anticorps monoclonal humain contre la glycoproteine e2 du virus de l'hepatite c

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08759309

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08759309

Country of ref document: EP

Kind code of ref document: A2